New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage

Table 3 Pharmacokinetic parameters of entecavir multiple doses in Bergman’s review

Dose (mg/d)	AUC (ng/h/mL)	Cmax (ng/mL)	Tmax (h)	T1/2 (h)
20	545.6 ± 57.9	179.8 ± 34.8	1.0	142.5 ± 55.5
10	304.3 ± 35.6	99.9 ± 13.7	0.75	127.5 ± 41.8
5.0	145.8 ± 28.4	46.2 ± 6.4	0.88	91.3 ± 57.9
2.5	71.6 ± 10.3	22.8 ± 5.7	0.75	115.7 ± 37.2
1.0	26.38 ± 12	8.24 ± 16	0.75	148.89 ± 39.5
0.5	14.78 ± 17	4.23 ± 9	1.0	129.9 ± 17.28
0.1	2.5 ± 21	0.6 ± 29	1.0	127.69 ± 91.44

Data are presented as the mean ± SD. Source: A1463002 and A1463033 clinical studies; AUC: Area under the concentration-time curve.